Literature DB >> 16921173

Remyelination is extensive in a subset of multiple sclerosis patients.

Peter Patrikios1, Christine Stadelmann, Alexandra Kutzelnigg, Helmut Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, Wolfgang Brück, Claudia Lucchinetti, Hans Lassmann.   

Abstract

Although spontaneous remyelination does occur in multiple sclerosis lesions, its extent within the global population with this disease is presently unknown. We have systematically analysed the incidence and distribution of completely remyelinated lesions (so-called shadow plaques) or partially remyelinated lesions (shadow plaque areas) in 51 autopsies of patients with different clinical courses and disease durations. The extent of remyelination was variable between cases. In 20% of the patients, the extent of remyelination was extensive with 60-96% of the global lesion area remyelinated. Extensive remyelination was found not only in patients with relapsing multiple sclerosis, but also in a subset of patients with progressive disease. Older age at death and longer disease duration were associated with significantly more remyelinated lesions or lesion areas. No correlation was found between the extent of remyelination and either gender or age at disease onset. These results suggest that the variable and patient-dependent extent of remyelination must be considered in the design of future clinical trials aimed at promoting CNS repair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16921173     DOI: 10.1093/brain/awl217

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  227 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Stem cell transplantation in multiple sclerosis: current status and future prospects.

Authors:  Gianvito Martino; Robin J M Franklin; Anne Baron Van Evercooren; Douglas A Kerr
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

3.  Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells.

Authors:  LiPing Liu; Lindsey Darnall; Taofang Hu; Karen Choi; Thomas E Lane; Richard M Ransohoff
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

Review 4.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

5.  Evaluation strategy to determine reliable demyelination in the cuprizone model.

Authors:  Uta Chrzanowski; Christoph Schmitz; Anja Horn-Bochtler; Anne Nack; Markus Kipp
Journal:  Metab Brain Dis       Date:  2019-01-03       Impact factor: 3.584

6.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

7.  Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination.

Authors:  Andrew V Caprariello; Saisho Mangla; Robert H Miller; Stephen M Selkirk
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

8.  Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS.

Authors:  Regina C Armstrong
Journal:  Future Neurol       Date:  2007-11

Review 9.  Myelin repair strategies: a cellular view.

Authors:  Vittorio Gallo; Regina C Armstrong
Journal:  Curr Opin Neurol       Date:  2008-06       Impact factor: 5.710

10.  Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair.

Authors:  Allan J Bieber; Kanitta Suwansrinon; Jason Kerkvliet; Weidong Zhang; Larry R Pease; Moses Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.